Form 4: Prelude Therapeutics Director Victor Sandor Acquires 23,500 Stock Options
SEC Form 4 Filing
Director Victor Sandor acquired 23,500 stock options in Prelude Therapeutics on June 14, 2024, according to a Form 4 filing.
Summary
- Victor Sandor, a director of Prelude Therapeutics Inc., acquired 23,500 stock options on June 14, 2024.
- The exercise price of these options is $3.90.
- The options will fully vest upon the earlier of the Issuer's next annual stockholder meeting, or the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- The options expire on June 13, 2034.
- Following the transaction, Sandor directly owns 23,500 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock option grants, indicating a neutral sentiment.
Industry Context
This is a routine disclosure of stock option grants to a company director, a common practice in publicly traded companies to align management's interests with those of shareholders.
Stakeholder Impact
- The stock option grant aligns the director's interests with those of shareholders, potentially incentivizing value creation.
Key Dates
| Date | Description |
|---|---|
| 06/14/2024 | Date of transaction: Victor Sandor acquired 23,500 stock options. |
| 06/14/2024 | Grant date of the stock options. |
| 06/13/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.